Purpose of the Review To provide an up-to-date review of the incidence of stroke and large
vessel occlusion (LVO) around the globe, as well as the eligibility and access to IV …

Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …

Background Tenecteplase is an effective thrombolytic agent for eligible patients with stroke
who are treated within 4.5 hours after the onset of stroke. However, data regarding the …

Intravenous thrombolysis is the only approved systemic reperfusion treatment for patients
with acute ischaemic stroke. These European Stroke Organisation (ESO) guidelines provide …

Importance Stroke is the fifth leading cause of death and a leading cause of disability in the
United States, affecting nearly 800 000 individuals annually. Observations Sudden …

Objectives: Concise “synthetic” review of the state of the art of management of acute
ischemic stroke. Data Sources: Available literature on PubMed. Study Selection: We …

Magnetic resonance imaging (MRI) is an important imaging modality in stroke. Computer
based automated medical image processing is increasingly finding its way into clinical …

Stroke is the leading cause of long term disability in developed countries and one of the top
causes of mortality worldwide. The past decade has seen substantial advances in the …

Ischemic stroke is the main cause of death and the most common cause of acquired physical
disability worldwide. Recent demographic changes increase the relevance of stroke and its …

The treatment of acute ischemic stroke continues to advance. The mainstay of treatment
remains intravenous thrombolysis with alteplase. Recent studies demonstrated that later …